Case 45 Ltd have created a generalisable AI engine capable of decoding cancer evolution and exploiting each individual tumour’s unique ecosystem. This will allow doctors to get ahead of cancer, prescribe optimised treatments, and ultimately defeat it. The system integrates a range of medical data with AI and tissue images to make AI-based digital tests that are faster, cheaper, and more accurate than alternatives.
Dr Khalid AbdulJabbar is CEO and co-founder of Case 45, is responsible for leading all fronts of the business. He is participating in the Shott Scale up Accelerator to support his, and the company’s, development around managing, leading, and motivating an experienced team as the company grows. He recognises that managing and interacting with consultants and experts needs a different set of skills. He also thinks strategy execution, especially about how to navigate executing a disruptive strategy is another area that will need support.
Dr AbduJabbar plans to use the Shott Scale up Accelerator to support attending the Next-Level Leadership course at LBS, London. It aims to strengthen a leader’s ability to be a good strategic leader — to lead by inspiring and coaching, as well as focusing on high-performance people skills. He recognises that the company will benefit from new perspectives on maintaining a culture with a focused sense of purpose at the top.
He also wants to use the networking and mentorship to expand his circle and learn from the experience of entrepreneurs and founders in the life sciences domain. These contacts will help to address the significant management responsibilities that a growing team brings. Over the next 12 to 18 months Case 45 are looking to build a team to launch a clinical testing product as well as securing extra investment and continuing to create an innovative culture. The company is working in a growing sector – the digital oncology market in the UK and US is currently $1.5B for lung and breast cancer indications alone.
